Steroid-resistant acute rejection after cadaveric liver transplantation: Experience from one single center

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 5, 2014, Pages 592-597

  Wu, Linwei ^a   Tam, Ngalei ^a,b   Deng, Ronghai ^a   Wu, Chenglin ^a   Chen, Philip ^c   Wang, Dongping ^a   He, Xiaoshun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BASILIXIMAB; DACLIZUMAB; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; GLUCOCORTICOID;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CADAVER; CANCER RECURRENCE; CANCER SURGERY; CHRONIC LIVER FAILURE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG DOSE INCREASE; DRUG FEVER; DRUG MEGADOSE; FEMALE; GRAFT RECIPIENT; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; MUSCLE DISEASE; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIMARY TUMOR; RETRANSPLANTATION; RETROSPECTIVE STUDY; STEROID RESISTANT ACUTE REJECTION; STEROID THERAPY; SURGICAL MORTALITY; SURVIVAL TIME; TREATMENT RESPONSE; TUBERCULOSIS; ACUTE DISEASE; ADOLESCENT; DRUG RESISTANCE; EVALUATION STUDY; GRAFT REJECTION; MIDDLE AGED; YOUNG ADULT;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CADAVER; DRUG RESISTANCE; FEMALE; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84912522207     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2014.04.005     Document Type: Article

References (26)

1. Matinlauri I.H., Nurminen M.M., Hockerstedt K.A., Isoniemi H.M. Changes in liver graft rejections over time. Transplant Proc 2006, 38:2663-2666.
2. McAlister V.C., Haddad E., Renouf E., Malthaner R.A., Kjaer M.S., Gluud L.L. Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 2006, 6:1578-1585.
3. Neil D.A., Hubscher S.G. Current views on rejection pathology in liver transplantation. Transpl Int 2010, 23:971-983.
4. Aydogan C., Sevmis S., Aktas S., Karakayali H., Demirhan B., Haberal M. Steroid-resistant acute rejections after liver transplant. Exp Clin Transplant 2010, 8:172-177.
5. Schmitt T.M., Phillips M., Sawyer R.G., Northup P., Hagspiel K.D., Pruett T.L., et al. Anti-thymocyte globulin for the treatment of acute cellular rejection following liver transplantation. Dig Dis Sci 2010, 55:3224-3234.
6. Munoz L.E., Nanez H., Rositas F., Perez E., Razo S., Cordero P., et al. Long-term complications and survival of patients after orthotopic liver transplantation. Transplant Proc 2010, 42:2381-2382.
7. Fernandes M.L., Lee Y.M., Sutedja D., Wai C.T., Isacc J., Prabhakaran K., et al. Treatment of steroid-resistant acute liver transplant rejection with basiliximab. Transplant Proc 2005, 37:2179-2180.
8. Nakanishi C., Kawagishi N., Sekiguchi S., Akamatsu Y., Sato K., Miyagi S., et al. Steroid-resistant late acute rejection after a living donor liver transplantation: case report and review of the literature. Tohoku J Exp Med 2007, 211:195-200.
9. Demirag A., Kalayci M., Ekci B., Gulcelik T., Gokce O. Sirolimus for rescue of steroid and anti-thymocyte globulin-resistant recurrent acute rejection after liver transplantation: report of one case. Transplant Proc 2009, 41:435-436.
10. Kawagishi N., Satoh K., Enomoto Y., Akamatsu Y., Sekiguchi S., Satomi S. Usage of deoxyspergualin on steroid-resistant acute rejection in living donor liver transplantation. Tohoku J Exp Med 2006, 208:225-233.
11. Pfitzmann R., Klupp J., Langrehr J.M., Uhl M., Neuhaus R., Settmacher U., et al. Mycophenolatemofetil for immunosuppression after liver transplantation: a follow-up study of 191 patients. Transplantation 2003, 76:130-136.
12. Aw M.M., Verma A., Rela M., Heaton N., Mieli-Vergani G., Dhawan A. Long-term outcome of mycophenolate mofetil rescue therapy for resistant acute allograft rejection in pediatric liver transplant recipients. Liver Transpl 2008, 14:1303-1308.
13. Aw M.M., Taylor R.M., Verma A., Parke A., Baker A.J., Hadzic D., et al. Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transpland recipients: a preliminary experience. Transplantation 2003, 75:796-799.
14. Orr D.W., Portmann B.C., Knisely A.S., Stoll S., Rela M., Muiesan P., et al. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation. Transplant Proc 2005, 37:4373-4379.
15. Platz K.P., Mueller A.R., Neuhaus P. Indications for mycofenolate mofetil therapy after liver transplantation. Transplant Proc 1997, 29:2880-2881.
16. Akamatsu N., Sugawara Y., Tamura S., Matsui Y., Kaneko J., Makuuchi M. Efficacy of mycofenolate mofetil for steroid-resistant acute rejection after living donor liver transplantation. World J Gastroenterol 2006, 12:4870-4872.
17. Musat A.I., Agni R.M., Wai P.Y., Pirsch J.D., Lorentzen D.F., Powell A., et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011, 11:500-510.
18. Bahra M., Neumann U.P., Jacob D., Langrehr J.M., Neuhaus P. Repeated steroid pulse therapies in HCV-positive liver recipients: significant risk factor for HCV-related graft loss. Transplant Proc 2005, 37:1700-1702.
19. Egawa H., Teramukai S., Haga H., Tanabe M., Fukushima M., Shimazu M. Present status of ABO-incompatible living donor liver transplantation in Japan. Hepatology 2008, 47:143-152.
20. Reich D.J., Fiel I., Guarrera J.V., Emre S., Guy S.R., Schwartz M.E., et al. Liver transplantation for autoimmune hepatitis. Hepatology 2000, 32:693-700.
21. Brusa P., Casullo R., Dosio F., Cattel L., Beltramini S., Chiappetta R., et al. OKT3 monitoring in the treatment of steroid-resistant acute rejection of hepatotransplant recipients. Eur J Drug Metab Pharmacokinet 1998, 23:301-306.
22. Go M.R., Bumgardner G.L. OKT3 (muromonab-CD3) associated hepatitis in a kidney transplant recipient. Transplantation 2002, 73:1957-1959.
23. Platz K.P., Mueller A.R., Zytowski M., Bechstein W.O., Blumhardt G., Lobeck H., et al. OKT3 vs FK 506 rescue management of acute steroid-resistant and chronic rejection. Transplant Proc 1995, 27:1111-1113.
24. Sevmis S., Emiroglu R., Karakayali F., Yagmurdur M.C., Dalgic A., Moray G., et al. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation. Transplant Proc 2005, 37:3016-3018.
25. Goralczyk A.D., Hauke N., Bari N., Tsui T.Y., Lorf T., Obed A. Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies. Hepatology 2011, 54:541-554.
26. Alvarez Castro A.M., Seijo Rios S., Molina Perez E., Castroagudin J.F., Varo Perez E. [Basiliximab in the treatment of acute steroid-resistant rejection after liver transplantation]. Gastroenterol Hepatol 2012, 35:649-651.